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Abstract
Aims/hypothesis The aim of this study was to examine whether cognitive function in early and later life, and decline in cognitive
function from age 70 to 79 years, are associated with high blood glucose, as measured by HbA1c, at baseline (age 70), and
changes in blood glucose from age 70 to 79.
Methods Participants (n = 1091) in the Lothian Birth Cohort of 1936were examined. Fourteen tests were used to assess cognitive
functions, grouped into four domains: visuospatial ability, processing speed, memory and crystallised ability. Test results, and
measurements of HbA1c and other health variables, were collected at each of four waves of assessment: at the mean age of 70, 73,
76 and 79 years. Data on cognitive function at age 11 was also available for this cohort. Latent growth curve modelling was
performed and statistical controls for known risk factors were introduced.
Results Higher age 11 cognitive function predicted lower HbA1c level at age 70 (p < 0.001). Higher cognitive function at age 70
was related to a comparatively smaller increase in HbA1c levels from age 70 to 79 (p < 0.001). HbA1c from age 70 to 79 did not
have any consistent association with change in cognitive function from age 70 to 79. These associations survived adjustments for
age, sex, education, APOE*ε4, smoking history, cardiovascular disease history, hypertension history, BMI and corrections for
multiple testing.
Conclusions/interpretation Our results show that, among older individuals, high blood glucose is consistently predicted
by lower cognitive function. Clinical care that examines and tracks cognitive function, while also taking the positive
effects of maintaining cognitive function and emulating healthy behaviours associated with higher cognitive function
into account, may be one approach for protecting at-risk individuals from elevated blood glucose and subsequent type 2
diabetes mellitus.
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Abbreviations
CVD Cardiovascular disease
LBC1936 Lothian Birth Cohort of 1936
LGCM Latent growth curve model
WAIS Wechsler Adult Intelligence Scale
WMS Wechsler Memory Scale
Introduction
As the prevalence of type 2 diabetes mellitus has grown world-
wide, so has the need to understand related health implications
such as the link between diabetes and cognitive function. Type
2 diabetes is associated with an increased risk of cognitive
decline and dysfunction, including dementia [1]. Diabetes-
associated cognitive impairment is expected to become more
prevalent as life expectancy for individuals with diabetes
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increases worldwide, highlighting a need to understand the re-
ciprocal dynamic progression of type 2 diabetes and cognitive
decline. The present study investigates the relationships be-
tween cognitive change and HbA1c measurements, one of the
most important risk metrics in type 2 diabetes.
Impaired glucose control, confirmed by HbA1c measure-
ment, is present in and predicts the development of type 2
diabetes, even though the syndrome may be asymptomatic
and go undetected for years [2]. High HbA1c is also associated
with cognitive decline in older populations, in both healthy
individuals [3] and those diagnosed with type 2 diabetes [4, 5].
Additionally, HbA1c levels are associated with micro- and
macrovascular complications [2, 6], reduction in brain volume
[7, 8], and dementia [9]. The HbA1c–cognitive function rela-
tionship could be causative: the toxic generation of free radi-
cals which accompanies increased HbA1c may cross over into
the brain, affecting cognitive functions [10].
Previous work on cognitive functioning and diabetes has
focused on controlling for known risk factors such as vascular
disease and the APOE*ε4 allele, as well as identifying indepen-
dent risk factors such as glucose peaks [11] and insulin resis-
tance [12] that could be linked to cognitive decline. However,
whereas type 2 diabetes and high blood glucose are associated
with poorer cognitive function later in life, evidence for reverse
causation also exists, suggesting that lower prior cognitive
function might contribute to type 2 diabetes aetiology [13].
Many samples are unable to address these types of questions
because they lack a longitudinal design that tracks relevant
variables, cognitive and health-related, in the same individuals
across discrete waves of assessment. HbA1c is a useful marker
for studying the development of diabetes in this way, as it has
good specificity and sensitivity to detect type 2 diabetes and
also measures the severity of the disease [6, 14–16].
This study’s aim was to characterise, across the eighth de-
cade of life, parallel changes in cognitive functions and high
blood glucose (measured by HbA1c), and to investigate asso-
ciations between baseline levels and change in these measures
over time. Our study used four waves of data from the Lothian
Birth Cohort of 1936 (LBC1936), a narrow age cohort of over
1000 community-dwelling people tested in four waves from
age 70 to 79 years. LBC1936 also provides cognitive function
data from age 11, as well as other control variables. This
sample allowed us to assess two non-mutually exclusive hy-
potheses: higher HbA1c at age 70 is associated with relatively
greater cognitive decline from age 70 to 79 [17–19]; and the
reverse causative hypothesis, i.e. that lower initial cognitive
function and relatively greater cognitive decline are associated
with subsequently higher HbA1c levels [13, 20].
Methods
Study population LBC1936 is a community-dwelling sample of
1091 initially healthy individuals. All were born in 1936 and
were followed up in four waves of one-to-one cognitive and
health testing between 2004 and 2017, at mean ages 70, 73, 76
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and 79 years. Details on the background, recruitment and data
collection procedures are available [21, 22]. Participants provid-
ed written informed consent. Ethics permissions were obtained
from the Multicentre Research Ethics Committee for Scotland
(wave 1, MREC/01/0/56), the Lothian Research Ethics
Committee (wave 1, LREC/2003/2/29) and the Scotland A
Research Ethics Committee (waves 2–4, 07/MRE00/58).
Cognitive function When they were approximately 11 years
old, 1028 members of the LBC1936 sat Moray House Test
No. 12, a broad cognitive ability test that included word clas-
sification, proverbs, spatial items and arithmetic. The test cor-
related about 0.8 with the Terman–Merrill revision of the
Stanford–Binet test, providing concurrent validity [23].
In older age, cognitive function is known to decline across
multiple domains [24]. Age effects also act on overall cognitive
function, a superordinate factor of the lower function domains
[24]. We included tests to measure three important cognitive
function domains that decline with age: visuospatial ability,
processing speed and memory. We also tested crystallised abil-
ity, which remains relatively stable in later life [25]. All four
domains also contribute to overall cognitive ability [26]. These
relationships among cognitive tests and domains are described
in the Statistical Analyses section below.
Cognitive functions in waves 1–4 were assessed using 14
individually administered cognitive tests at the same clinical
research facility and using the same equipment and procedure
for all four waves. The tests are fully described and referenced
in an open-access protocol article [21]. The visuospatial do-
main consisted of matrix reasoning and block design from the
Wechsler Adult Intelligence Scale (WAIS) [27], and spatial
span forward and backward from the Wechsler Memory
Scale (WMS) [28]. Processing speed was measured through
symbol search and digit symbol substitution from the WAIS,
plus four-choice reaction time [29] and inspection time [30,
31]. Memory was assessed using verbal paired associates and
logical memory from the WMS [28], and the letter–number
sequencing and digit span backward subtests of the WAIS
[27]. Crystallised ability was measured through the National
Adult Reading Test [32], Wechsler Test of Adult Reading [33]
and a phonemic verbal fluency test [34].
Clinical diabetes measures For each individual during each
wave, HbA1c concentrations were measured using a
Menarini HA-8160 analyser (Wokingham, UK). Diabetes di-
agnosis status was independently recorded. Twelve individ-
uals with type 1 diabetes were excluded from further analyses.
Covariates Three variable sets were evaluated as potential
confounders. The first set defined our baseline control covar-
iates: sex, age (z scored), age 11 cognitive function (z scored),
and years of education (z scored). The second set included the
available cardiovascular risk factors, obtained from interview
and genetic testing: high BP history (no/yes), cardiovascular
disease (CVD) history (no/yes), smoking history (current/for-
mer/never), and the presence of an APOE*ε4 allele. The third
set contained only BMI (z scored), recorded at every testing
wave and introduced to our analyses separately from the other
cardiovascular variables because BMI is strongly associated
with HbA1c and can have a confounding effect.
Statistical analysesAll four LBC1936 waves were analysed in
latent growth curve models (LGCMs), a structural equation
modelling technique that allows the user simultaneously to
define and analyse multiple latent and measured variables
[35]. For each variable modelled longitudinally, LGCMs
model level (i.e. an intercept) and slope (i.e. a trajectory of
change) variables. We modelled cognitive function using a
hierarchical ‘factor of curves’ model, previously established
with these data [26]. For each cognitive test we modelled a
level (essentially the age 70 baseline) and a linear slope (the
change between age 70 and 79, taking all four measurement
occasions into account); for each cognitive domain (see
Cognitive function, above) a latent level and linear slope var-
iable were correspondingly composed of the individual tests’
latent level and latent slope variables. At the top of this cog-
nitive hierarchy, latent levels and slopes for overall cognitive
function were formed from the level and slope variables of
each cognitive domain. For HbA1c variables, the same ap-
proach was taken, but only a pair of level and slope variables
were defined for this outcome variable, as no hierarchical
structure exists. A structural diagram to illustrate these mea-
sured and latent variables is presented in Fig. 1. We also in-
vestigated quadratic slope variables for both cognitive func-
tion and HbA1c, but models including quadratic components
either would not converge successfully, or they fit very poorly
and could not be trusted to produce reliable estimates.
Put simply, HbA1c level is analogous to blood glucose at
the study’s beginning (age 70 years), and HbA1c slope is
analogous to the magnitude at which blood glucose increases
over the following decade. Cognitive function level is analo-
gous to cognitive function at age 70 and is known to be highly
correlated with cognitive function at age 11 [26], demonstrat-
ing the stability of cognitive function across a lifetime. The
slope of cognitive function represents the rate at which cogni-
tive functions change (mostly decrease, in fact) over subse-
quent waves, which is otherwise known as cognitive decline.
Control covariates that applied to all waves of data (sex, age
11 cognitive function, years of education, APOE*ε4 status and
smoking history) were regressed on to the intercept and slope
variables for latent levels and slopes, including those for the
domains of cognitive function, but not on to the levels or slopes
of individual cognitive tests. Control covariates that were
related to physical condition and could differ between waves
(age, history of high BP, history of CVD, and BMI) were
regressed on to the individual HbA1c measurements.
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Model coefficients were estimated using full information
maximum likelihood, i.e. all data were used for all partici-
pants, even individuals who did not complete all waves.
Standard errors were calculated using the robust Huber–
White method, and p values were computed using the Yuan–
Bentler scaled test statistic [36]. The false discovery rate cor-
rection for multiple testing was applied to the variables in each
model that were not control covariates, which included the
associations between the latent variables of cognitive function
and its subdomains and HbA1c. All analyses were conducted
in the R programming language, version 3.3.2 (R Foundation
for Statistical Computing, Vienna, Austria), using the latent
variable analysis (lavaan) package for modelling [37].
Results
Cohort characteristics Demographic and clinical characteris-
tics of the study population at all four waves are presented in
Table 1. Electronic supplementary material (ESM) Table 1
presents wave 1–3 descriptions of study completers only, i.e.
those individuals who remained present in wave 4.
Individuals with type 2 diabetes were more likely than
healthy individuals to have a history of CVD or high BP
(Table 1). The type 2 diabetes group included more men, as
well as more current and former smokers. Individuals with
type 2 diabetes had higher BMI and HbA1c levels; in all waves
their mean HbA1c was above the diagnostic threshold of
48 mmol/mol (6.5%). Individuals with type 2 diabetes had
lower age 11 cognitive function and scored more poorly than
healthy individuals on all cognitive tests across all four waves.
To illustrate cognitive decline across domains, we plotted the
discrete overall cognitive function and domain scores across all
four waves, with individuals categorised as either healthy or
showing a clinical or biochemical (HbA1c above diagnostic
threshold) type 2 diabetes diagnosis at wave 1 (Fig. 2). Figure
2 represents study completers only, because including data from
all study participants would bias the means of later waves in the
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Fig. 1 Simplified path diagram of the hierarchical factor of curves growth
model of cognitive function and HbA1c. Circles represent latent variables
and squares represent measured variables. Growth curves, including a
latent level and slope factor, were estimated for each cognitive test, and
the intercepts and slopes were analysed in a hierarchical model which
contained domain and overall factors of both level and slope. Basis coef-
ficients (loadings on the individual test slopes) were fixed at 0, 2.96, 6.72
and 9.79 to precisely represent the amount of time passing between as-
sessments. All loadings on latent level were fixed at 1. Dashed lines
indicate the relationships between covariates that were fixed across waves
and the overall and domain latent variables. Dotted lines indicate the
relationships between covariates that differed between waves and indi-
vidual measurements at different waves. To preserve interpretability, not
all covariate relationships are shown. Solid double-arrowed lines indicate
correlations between latent variables. Solid single arrowed lines indicate
the variables that load on latent variables. Although only two domains
and four tests are shown here, the full model used all 14 tests in the four
domains, as described in Methods
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positive direction, making plots unrepresentative of the sample.
As expected, with the exception of crystallised ability, the
curves show clear declines across all other cognitive domains
in individuals with and without type 2 diabetes; however, cog-
nitive function was worse in individuals with type 2 diabetes.
Figure 2 is for illustration purposes only.
Age 70–79 cognitive performance and HbA1c Figure 3 shows
the relationships between the level and slope estimates of
HbA1c and overall cognitive function. Three models are pre-
sented, with control variables added cumulatively, as de-
scribed in Methods. The diagrams present the results for over-
all cognitive function; domain-specific results can be found in
ESM Table 2. The effects of control variables on the level and
slope estimates are also presented in Fig. 3, whereas disease-
relevant effects of control variables, measured at each wave,
are presented separately in ESMTable 2. Model fit statistics of
all LGCMs indicated a good fit (root mean square error of
approximation [RMSEA] <0.33; standardised root mean re-
sidual [SRMR] <0.62; comparative fit index [CFI] >0.939;
Tucker–Lewis index [TLI] >0.936; see ESM Table 3 for com-
plete fit statistics).
Age 11 cognitive function made significant contributions
to both cognitive function level (β > 0.4, coefficient of partial
determination ρ2 > 0.35) and HbA1c level (β > −0.066, ρ2 >
0.007) at age 70; that is, higher childhood cognitive function
was associated with higher cognitive function and lower
HbA1c concentration at age 70. More education was also
Table 1 Descriptive statistics for cognitive, demographic and clinical variables
Variable Wave 1 (n = 1091) Wave 2 (n = 866) Wave 3 (n = 697) Wave 4 (n = 548)
T2D No T2D T2D No T2D T2D No T2D T2D No T2D
Participants, n (%) 76 (6.97) 1015 (93.0) 84 (9.70) 782 (90.3) 75 (10.8) 622 (89.2) 66 (12.0) 482 (88.0)
Female, n (%) 27 (2.47) 516 (47.3) 28 (3.23) 390 (45.0) 24 (3.44) 313 (44.9) 26 (4.74) 247 (45.1)
Ever a smoker, n (%) 51 (4.67) 539 (49.4) 50 (5.77) 401 (46.3) 46 (6.60) 301 (43.2) 39 (7.12) 212 (38.7)
Ever had CVD, n (%) 32 (2.93) 236 (21.6) 35 (4.04) 215 (24.8) 34 (4.88) 202 (29.0) 25 (4.56) 179 (32.7)
Ever had high BP, n (%) 56 (5.13) 377 (34.6) 58 (6.70) 367 (42.4) 57 (8.18) 321 (46.1) 51 (9.31) 264 (48.2)
BMI, kg/m2 30.5 (4.52) 27.6 (4.28) 30.1 (5.04) 27.7 (4.32) 29.6 (4.76) 27.5 (4.39) 29.7 (5.52) 27.1 (4.34)
HbA1c, mmol/mol 59.0 (13.7) 40.0 (6.08) 53.1 (9.71) 37.9 (5.01) 53.2 (9.30) 39.4 (4.95) 55.1 (11.6) 38.4 (4.30)
HbA1c, % 7.5 (3.4) 5.8 (2.7) 7.0 (3.0) 5.6 (2.6) 7.0 (3.0) 5.8 (2.6) 7.2 (3.2) 5.7 (2.5)
Years of education 10.5 (1.09) 10.7 (1.13) 10.4 (1.02) 10.8 (1.15) 10.5 (1.06) 10.8 (1.15) 10.5 (1.09) 10.9 (1.18)
Age 11 cognitive function 94.4 (16.8) 100.0 (14.8) 96.5 (17.1) 101.0 (15) 96.7 (16.9) 102.1 (15.0) 96.5 (17.2) 103.0 (14.9)
Visuospatial ability domain
Matrix reasoning 11.9 (5.28) 13.6 (5.10) 12.1 (4.51) 13.3 (5.00) 12.0 (5.06) 13.2 (4.88) 12.0 (4.78) 13.0 (5.06)
Block design 32.3 (11.0) 33.9 (10.3) 30.3 (9.18) 34.0 (10.1) 30.6 (8.95) 32.4 (10.1) 29.9 (8.68) 31.4 (9.75)
Spatial span 7.07 (1.65) 7.55 (1.44) 6.65 (1.70) 7.11 (1.59) 6.80 (1.74) 7.08 (1.57) 6.71 (1.48) 6.74 (1.62)
Crystallised ability domain
NART 31.1 (9.63) 34.7 (7.98) 31.9 (8.70) 34.6 (8.08) 32.5 (8.76) 35.3 (7.89) 34.2 (9.38) 35.8 (8.01)
WTAR 37.3 (8.96) 41.3 (6.95) 38.8 (7.49) 41.2 (6.87) 39.0 (7.67) 41.3 (6.91) 40.2 (8.06) 41.8 (6.87)
Verbal fluency 40.1 (13.9) 42.6 (12.4) 39.4 (12.6) 43.6 (12.9) 40.1 (13.2) 43.2 (12.7) 41.7 (14.2) 43.9 (13.2)
Memory domain
Logical memory 68.2 (19.0) 71.7 (17.9) 70.2 (19.6) 74.7 (17.6) 71.9 (20.6) 74.9 (19.0) 71.4 (22.6) 72.9 (20.1)
VPA 25.4 (9.08) 26.5 (9.14) 25.8 (9.52) 27.3 (9.45) 24.3 (8.87) 26.7 (9.61) 26.7 (9.96) 27.2 (9.51)
Digit span 7.30 (2.47) 7.77 (2.24) 7.27 (2.10) 7.87 (2.30) 7.19 (2.39) 7.84 (2.36) 7.08 (1.79) 7.62 (2.22)
LNS 10.2 (3.58) 11.0 (3.12) 10.3 (3.07) 11.0 (3.07) 9.7 (2.99) 10.6 (2.98) 9.4 (2.82) 10.2 (2.90)
Processing speed domain
Symbol search 22.3 (7.45) 24.9 (6.27) 23.2 (6.49) 24.8 (6.13) 23.7 (5.89) 24.7 (6.52) 21.6 (6.37) 22.9 (6.66)
Digit–symbol coding 50.8 (12.0) 57 (12.9) 51.3 (13.2) 56.9 (12.1) 49.5 (13.6) 54.3 (12.8) 48.2 (13.5) 51.6 (12.9)
Inspection time 110 (10.4) 112 (11.0) 108 (11.5) 112 (11.8) 108 (13.0) 110 (12.5) 104 (14.3) 107 (13.5)
Reaction time 0.676 (0.107) 0.640 (0.084) 0.687 (0.122) 0.645 (0.085) 0.700 (0.116) 0.676 (0.101) 0.706 (0.112) 0.706 (0.114)
MMSE 28.1 (2.00) 28.8 (1.37) 28.4 (1.93) 28.8 (1.35) 28.1 (1.74) 28.7 (1.68) 28.2 (1.86) 28.6 (2.08)
Data are presented as n (%) or mean (SD)
LNS, letter–number sequencing; MMSE, Mini Mental State Examination; NART, National Adult Reading Test; T2D, type 2 diabetes, defined as self-
reported physician diagnosis of diabetes; VPA, visual paired associates; WTAR, Wechsler Test of Adult Reading
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associated with better cognitive function in older age, though
to a lesser degree (β > 0.12, ρ2 > 0.026). These findings are
consistent with those previously reported [13, 20, 38].
The relationship between cognitive function level at age 70
and cognitive function slope was robust and did not change
when covariates were added (r = 0.002, ρ2 = 4 × 10−6), but the
association was small enough that we can only infer that cog-
nitive function level and slope have no strong relationship.
This is likely due to low covariance between cognitive func-
tion level and slope; or, in other words, regardless of an indi-
vidual’s starting cognitive function level, cognitive function
will consistently decline over the course of the eighth decade.
Significant associations of the same sign were found be-
tween HbA1c slope and both level and slope of cognitive
function in models. These results indicate that individuals
with higher cognitive function at age 70 maintain lower blood
glucose over the following decade, and these associations
remain in the presence of all control covariates. The associa-
tion between cognitive function level and HbA1c slope was as
large as r = −0.166 (ρ2 = 0.03), which was found after control-
ling for the influence of age 11 cognitive function and educa-
tion. The relationship between cognitive function slope and
HbA1c slope, while consistently positive and significant, was
small: at most it was r = 0.008 (ρ2 = 6.4 × 10−5) in the first
model (Fig. 3a), which includes the fewest controls.
Associations between HbA1c level and cognitive function
slope were significant but were not consistent across models
and were relatively small. Moreover, the association between
cognitive function level and HbA1c level was not always sig-
nificant, nor was it in the same direction across models. We
found no significant associations between HbA1c level and
slope in any of these models.
Associations between HbA1c growth curve estimates and
cognitive function at the domain level generally followed the
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Fig. 2 Trajectories of overall and
domain-specific cognitive
abilities in individuals with and
without type 2 diabetes in the
Lothian Birth Cohort 1936.
Diabetes was defined by reported
physician diagnosis or HbA1c
level >48 mmol/mol (6.5%) at
wave 1. (a) Overall cognitive
ability, composed of the four
specific cognitive domains:
visuospatial ability (b),
processing speed (c), memory (d)
and crystallised ability (e). Red
line and 95% confidence region,
individuals without diabetes; blue
line and 95% confidence region,
individuals with diabetes. These
plots only include data from
individuals with data available
from all four waves of the Lothian
Birth Cohort 1936 study, since
including data from all
individuals in these plots would
bias the means towards a positive
direction at older ages, making
them unrepresentative of the
whole sample
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associations found with overall cognitive function level and
slope (Fig. 3; ESM Table 2), with the exception of crystallised
ability, which, even in older individuals, tends not to decline
over time. In the first model, with the fewest controls, all
cognitive domain variables were significantly associated with
HbA1c level and slope, and this held true across subsequent
models, except for the slope variables of memory and
crystallised ability. Decline in memory and crystallised ability
was not associated with either HbA1c level or slope after con-
trols were included.
We conducted sensitivity analyses on our three structural
equation models; specifically, we fit the same models, exclud-
ing individuals from a wave if they had been given any type of
diabetes diagnosis. The resultant models were very similar to
the models presented in Fig. 3 (ESM Table 4); effect sizes
were generally reduced, and no previously small and/or un-
stable associations became robust in these models. We also
tested whether change in cognitive function that occurred be-
tween age 11 and age 70 was associated with HbA1c levels,
but while age 11 cognitive function significantly predicted
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Fig. 3 Path diagram of relationships between level and slope estimates of
overall cognitive function (CF) and HbA1c in the Lothian Birth Cohort
1936 from age 70 to 79 years. In (a), the model includes the covariates
shown, as well as age. In (b), the model includes the covariates shown, as
well as age and history of CVD and high BP, history of smoking and the
presence of an APOE*ε4 allele. In (c), the model includes all the covar-
iates shown, age, and history of CVD, history of high BP, smoking and
APOE*ε4, as well as BMI (the latter is demonstrated as a time-varying
covariate in ESM Table 2). Numbers presented are standardised estimates
with SEM in parentheses. Double-headed arrows between latent variables
(circles) indicate correlations. Single-headed arrows from covariates
(rectangles) indicate regression effects on latent variables. Dashed lines
indicate non-significant correlations, whilst solid lines and † indicate sig-
nificance; The false discovery rate correction for multiple testing was
applied to all tested relationships. Additional estimates for domains and
controls are presented in ESM Table 2
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HbA1c, change in cognitive function did not (ESM Results,
ESM Table 5).
Post hoc analyses of diagnosis status interacting with cogni-
tive function and HbA1c Individuals might change their behav-
iour once they are aware that they have type 2 diabetes. To test
whether or not higher functioning individuals may be better at
caring for themselves after diagnosis, we ran a repeated-
measures ANCOVA on the first two study waves, treating type
2 diabetes diagnosis, wave and overall cognitive function as
independent variables and HbA1c as the dependent variable.
Type 2 diabetes diagnosis (ω2 = 0.338, p < 0.0001), cognitive
function (ω2 = 0.004, p < 0.0001) and wave (ω2 = 0.023, p <
0.0001) all had individual main effects, as did the type 2 diag-
nosis and wave interaction (ω2 = 0.006, p < 0.0001). However,
type 2 diagnosis and cognitive function did not significantly
interact (ω2 < 0.001, p = 0.742), suggesting that knowledge of
one’s diagnosis is not related to higher functioning individuals
taking better care of themselves. No additional interactions in
the model were significant either. These results were robust to
the inclusion of control covariates (ESM Table 6).
In much the same way that cognitive function might
behaviourally impact post-diagnosis HbA1c, individuals with
type 2 diabetes who maintain low HbA1c measurements may
show cognitive differences from individuals with type 2 dia-
betes who do not maintain healthier HbA1c.We also tested this
is an ANCOVA framework, making cognitive function the
outcome variable, and including HbA1c, wave (1 or 2) and
type 2 diabetes diagnosis as independent variables. We found
main effects of type 2 diabetes diagnosis (ω2 = 0.014, p <
0.0001) and HbA1c (ω
2 = 0.006, p = 0.0001), but no effects
of wave or any interactions. These effects were robust to the
inclusion of covariates (ESM Table 7). Together, these find-
ings suggest that type 2 diabetes diagnosis and HbA1c are both
associated with cognitive function, but neither changes in di-
agnosis nor whether an individual with type 2 diabetes has
relatively low or high HbA1c appear to be related to cognitive
function.
Discussion
The results show that in an older narrow age cohort, tested on
four occasions between 70 and 79 years, lower cognitive func-
tion at 70 is associated with increases in HbA1c over the fol-
lowing decade. Cognitive function level is negatively corre-
lated with the slope of HbA1c, and this effect is robust to the
inclusion of all covariates, including age 11 cognitive func-
tion. Age 11 cognitive function itself is consistently and neg-
atively related to HbA1c level, which is consistent with previ-
ous reports of this sample [20, 39]. Together, these results
suggest that cognitive function consistently predicts blood
glucose later in life.
Other associations between slope and level estimates of
cognitive functions and HbA1c were generally small and were
inconsistent when different covariates were added. We found
no consistent relationships between HbA1c level and cognitive
function slope, which represents cognitive decline. If HbA1c
had a causative, negative effect on cognitive function, we
would expect to find this, but the largest association was
0.018 and in the opposite direction from what we would ex-
pect. The associations discussed thus far are visible in Fig. 2,
where one can see that the initial level of cognitive function is
lower in individuals with type 2 diabetes, though the rate of
decline is not obviously different.
We found a significant association between age 11 cogni-
tive function and HbA1c level starting at age 70 and cognitive
function level at age 70, but we did not find any relationships
between HbA1c level and age 70 cognitive function level or
change in cognitive function from ages 11 and 70. This sug-
gests that early life cognition, which is stable over the lifespan,
drives the cross-sectional association between cognitive func-
tion and HbA1c at age 70. In 1947, there was no HbA1c mea-
surement at age 11, so we cannot decide here whether early
cognitive function is causal to worsening blood glucose across
the life course to age 70, or whether cognitive functioning and
blood glucose track each other through the life course.
It is notable that age 11 cognitive function was not associ-
ated with HbA1c slope, but cognitive function level at age 70
was. This was surprising, given that cognitive function level at
age 70 was not reliably related to HbA1c level starting at the
same age. However, these findings are consistent with a lead-
lag effect: better cognitive functioning earlier in life predicts
lower blood glucose, but only later in life.
Early cognitive function is a major life course variable that
influences blood glucose and type 2 diabetes progression. In
this sample, sex had few effects on level and slope outcomes.
The strongest was with cognitive function level—men tended
to have higher cognitive function level in this sample. Years of
education display similar relationships: very small effects on
all level and slope estimates other than cognitive function
level, with which education showed positive relationships
(β > 0.12).
When introduced in model B, disease variables including
APOE*ε4 and hypertension and CVD history greatly reduced
the effect of cognitive function on HbA1c slope. Smoking
history, for example, had a notable effect on HbA1c level,
indicating that smokers were more likely to have higher
HbA1c at age 70. The impact of these variables suggests that
the association between cognitive function and later measure-
ments of HbA1c is related to health behaviours. One interpre-
tation of the results is that individuals with higher cognitive
function take better care of themselves: they smoke less, are
more active and have a healthier diet [40]. These associations
between cognitive function and health later in life have been
extensively investigated [41–43], including through diabetes
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epidemiology [13, 20]. However, our post hoc analyses dem-
onstrated that the relationship between cognitive function and
HbA1c could not be explained by participants with higher
cognitive function altering their behaviour more than those
with lower cognitive function when these participants become
aware of their type 2 diabetes diagnosis.
The extensive clinical and cognitive data that were available
across all four waves, over a decade, are clear strengths of this
study, as was the availability of a reliable cognitive function
measure at an early age. Moreover, the broad range of validated
cognitive tests allowed us to investigate both overall and do-
main level associations between cognitive function and blood
glucose. As the LBC1936 is a narrow age cohort, neither cohort
nor age effects could significantly bias our findings.
There were also limitations to this study that ought to be
considered. First, our sample featured relatively few individ-
uals diagnosed with type 2 diabetes, which limits the power of
the statistical analyses. This issue was somewhat ameliorated
by our use of HbA1c as an outcome, which captures fine-
grained information about diabetic and prediabetic status; nev-
ertheless, comparatively few individuals had clinically elevat-
ed blood glucose. Second, and similarly, dropout (most likely
due to mortality and frailty) was significant; almost half of the
original sample did not return by the fourth wave. Whereas
our models take existing and missing data into account, ulti-
mately these missing data limit our statistical power and
would particularly impact our analyses of slopes. For instance,
we might not have possessed the statistical power to detect
small changes in cognitive function that could have been driv-
en by high HbA1c. Third, we did not have any HbA1c mea-
surements from earlier in life, so we could not control for the
influence of type 2 diabetes precursors that might have existed
earlier in life. However, the prevalence of type 2 diabetes in
children and young adults is low [44] and would be lower still
in a cohort born in 1936 [20].
HbA1c not only predicts type 2 diabetes but is also associ-
ated with vascular complications [2, 6] and declines in both
cognitive function [3, 4, 9] and brain volume [7, 8]. However,
some prior findings are counterintuitive. For example, total
brain volume was increased in a group receiving targeted
glycaemic control therapy, but in spite of this no differences
were found in cognitive outcomes [7]. In general, it is difficult
to determine the direction of causality in the association be-
tween type 2 diabetes and cognitive decline, but the current
literature suggests that having type 2 diabetes causes greater
cognitive decline [11, 12, 19, 45, 46].
Our results support an alternative hypothesis, i.e. that cog-
nitive function predicts high blood glucose; however, we
stress that the two hypotheses are not mutually exclusive.
The best explanation for our results and the wider body of
research is that early life cognitive function contributes to
impairment of glucose tolerance and onset of type 2 diabetes.
Once an individual has developed diabetes, complication of
the disease could lead to later impairment in cognitive func-
tion. Our results also suggest that good cognitive function
continues to protect an individual from developing high blood
glucose, emphasising its possible importance in ameliorating
type 2 diabetes progression throughout the lifespan. Further
research into the mechanisms whereby cognitive function im-
pacts and is impacted by elevated blood glucose is warranted
in the pursuit of underused strategies for identifying at-risk
older individuals and protecting them from cognitive decline
and type 2 diabetes.
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